ArticleDermatology (Basel, Switzerland)2026
Generalized Pustular Psoriasis Confers Increased Risk of Pyoderma Gangrenosum: First Population-Based Evidence.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Generalized pustular psoriasis (GPP) and pyoderma gangrenosum (PG) are rare, severe neutrophilic dermatoses with overlapping autoinflammatory pathways. Although case reports suggest a link between GPP and PG, no population-based studies have quantified this risk.
methodsWe performed a retrospective cohort study using the TriNetX federated electronic health record network. Adults (≥18 years) with ICD-10 codes for GPP (L40.1) or non-GPP (L40.0-L40.9 excluding L40.1) from 2018 to 2023 were identified. Controls had no psoriasis diagnosis. Cohorts were 1:1 propensity score matched for age, sex, race, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and rheumatoid arthritis. The primary outcome was new PG diagnosis (L88) post-index. Hazard ratios (HRs) for PG were estimated via matched survival analysis.
resultsAfter matching, the GPP cohort (n = 44,187) had a significantly higher risk of PG than controls (n = 44,187; HR 5.14; 95% CI 2.77-9.53). Non-GPP patients (n = 393,833) also showed elevated PG risk versus controls (n = 393,833; HR 3.83; 95% CI 3.00-4.90). In direct comparison (n = 193,208 each), GPP had greater PG risk than non-GPP (HR 2.33; 95% CI 1.46-3.71). Median follow-up ranged from 687 to 886 days across comparisons.
conclusionThis first population-based evidence demonstrates that GPP confers a markedly increased risk of PG compared to both controls and other psoriasis subtypes. These findings underscore the need for heightened clinical vigilance for PG in GPP patients and may inform targeted surveillance strategies. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.